↓ Skip to main content

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling

Overview of attention for article published in Cancer Discovery, December 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#14 of 3,621)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
60 news outlets
blogs
2 blogs
twitter
94 tweeters
patent
29 patents
facebook
1 Facebook page
googleplus
1 Google+ user

Citations

dimensions_citation
497 Dimensions

Readers on

mendeley
453 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
Published in
Cancer Discovery, December 2017
DOI 10.1158/2159-8290.cd-17-0716
Pubmed ID
Authors

Aadel A. Chaudhuri, Jacob J. Chabon, Alexander F. Lovejoy, Aaron M. Newman, Henning Stehr, Tej D. Azad, Michael S. Khodadoust, Mohammad Shahrokh Esfahani, Chih Long Liu, Li Zhou, Florian Scherer, David M. Kurtz, Carmen Say, Justin N. Carter, David J. Merriott, Jonathan C. Dudley, Michael S. Binkley, Leslie Modlin, Sukhmani K. Padda, Michael F. Gensheimer, Robert B. West, Joseph B. Shrager, Joel W. Neal, Heather A. Wakelee, Billy W. Loo, Ash A. Alizadeh, Maximilian Diehn

Abstract

Identifying molecular residual disease (MRD) after treatment of localized lung cancer could facilitate early intervention and personalization of adjuvant therapies. Here we apply Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) circulating tumor DNA (ctDNA) analysis to 255 samples from 40 patients treated with curative intent for stage I-III lung cancer and 54 healthy adults. In 94% of evaluable patients experiencing recurrence, ctDNA was detectable in the first post-treatment blood sample, indicating reliable identification of MRD. Post-treatment ctDNA detection preceded radiographic progression in 72% of patients by a median of 5.2 months and 53% of patients harbored ctDNA mutation profiles associated with favorable responses to tyrosine kinase inhibitors or immune checkpoint blockade. Collectively, these results indicate that ctDNA MRD in lung cancer patients can be accurately detected using CAPP-Seq and may allow personalized adjuvant treatment while disease burden is lowest.

Twitter Demographics

The data shown below were collected from the profiles of 94 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 453 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 453 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 87 19%
Student > Ph. D. Student 54 12%
Other 47 10%
Student > Bachelor 33 7%
Student > Master 32 7%
Other 73 16%
Unknown 127 28%
Readers by discipline Count As %
Medicine and Dentistry 133 29%
Biochemistry, Genetics and Molecular Biology 93 21%
Agricultural and Biological Sciences 32 7%
Chemistry 7 2%
Pharmacology, Toxicology and Pharmaceutical Science 7 2%
Other 29 6%
Unknown 152 34%

Attention Score in Context

This research output has an Altmetric Attention Score of 533. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 November 2022.
All research outputs
#36,691
of 22,590,459 outputs
Outputs from Cancer Discovery
#14
of 3,621 outputs
Outputs of similar age
#1,038
of 451,284 outputs
Outputs of similar age from Cancer Discovery
#2
of 88 outputs
Altmetric has tracked 22,590,459 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,621 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.4. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,284 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 88 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.